Used as an intermediate in the synthesis of abiraterone derivatives, this compound plays a role in the development of pharmaceutical agents targeting prostate cancer. Its modified structure allows for enhanced metabolic stability and improved binding characteristics during drug formulation. It is primarily utilized in research settings for optimizing steroidogenesis inhibitors, contributing to the production of more effective and selective androgen biosynthesis inhibitors. The acetyl modification at the 3-position aids in controlling reactivity and solubility during synthetic processes, making it valuable in medicinal chemistry for creating novel analogs with potential therapeutic benefits.